Theratechnologies Shareholders Elect Directors, Appoint Auditors
Theratechnologies Elects New Board Chair
Theratechnologies Reports on Its Annual Meeting of Shareholders
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of
Express News | Theratechnologies Will Present Long-term Efficacy, Safety And Pharmacokinetic Data On The Use Of Its Lead Investigational TH1902 (Sudocetaxel Zendusortide), In Patients With Solid Tumors, At The American Society Of Clinical Oncology
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (Sudocetaxel Zendusortide) in Solid Tumors at 2024 ASCO Meeting
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing MONTREAL, May 02, 2024
Theratechnologies Announces Virtual Annual Meeting
Theratechnologies Announces Mailing of Management Proxy Circular in Connection With Its Annual Meeting of Shareholders
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
MONTREAL, April 11, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of
Earnings Call Summary | Theratechnologies(THTX.US) Q1 2024 Earnings Conference
The following is a summary of the Theratechnologies Inc. (THTX) Q1 2024 Earnings Call Transcript:Financial Performance:Theratechnologies Q1 2024 consolidated revenue fell below expectations.Net sales
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision
Theratechnologies (TH.TO) was at last look up near 6% in US premarket trade on Wednesday after reporting a narrower Q1 loss and an acceleration of the phase 1 trial of a drug for ovarian cancer. The s
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug
Theratechnologies (TH.TO) was at last look up near 6% in US premarket trade on Wednesday after reporting a narrower Q1 loss and an acceleration of the phase 1 trial of a drug for ovarian cancer. The s
Theratechnologies' Q1 Financials and Oncology Advances
Theratechnologies GAAP EPS of -$0.10 Beats by $0.04, Revenue of $16.2M Misses by $3.19M
Theratechnologies Brief: Citing Acceleration of Phase 1 Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer With Enrollment of Next Cohort of Patients Underway at Higher Dose Level
07:32 AM EDT, 04/10/2024 (MT Newswires) -- Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patien
Theratechnologies 1Q Rev $16.2M >THTX
Theratechnologies 1Q Rev $16.2M >THTX
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
Earnings Scheduled For April 10, 2024
Companies Reporting Before The Bell • Delta Air Lines (NYSE:DAL) is projected to report quarterly earnings at $0.35 per share on revenue of $12.55 billion. • Altamira Therapeutics (NASDAQ:CYTO) is est
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology(TM) Oncology Platform
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology Oncology Platform
Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft modelsSORT1 gene silencing results in drastic
Theratechnologies Strengthens Board With New Appointment
No Data